Research And Development Agreement Sample Contracts

Share Cite Term
Link

Embed (HTML)
Turnpoint Medical Devices, Inc. – Research and Development Agreement (August 11th, 2016)

This Research and Development Agreement (this "Agreement") executed this 29th day of October, 2014, is by and between Point Medical, Inc., a Delaware corporation ("PMI"), and Leveraged Developments LLC, a New Hampshire limited liability company ("LD"). PMI and LD are individually a "Party", and together are the "Parties," to this Agreement.

Enumeral Biomedical Holdings, Inc. – Collaborative Research and Development Agreement (March 30th, 2016)

This COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (this "Agreement") is entered into as of January 11, 2016 (the "Effective Date") by and between Enumeral Biomedical Holdings, Inc., a Delaware corporation with offices at 200 Cambridge Park Drive, Cambridge, MA 02140 (with its subsidiaries, "Enumeral"), and The University of Texas M. D. Anderson Cancer Center, a member institution of The University of Texas System ("System") and an agency of the State of Texas, with offices at 1515 Holcombe Blvd., Houston, Texas 77030 ("MDACC"). Each of MDACC and Enumeral is sometimes referred to individually herein as a "Party" and collectively as the "Parties".

Research and Development Agreement (August 21st, 2015)

This RESEARCH AND DEVELOPMENT AGREEMENT (the AGREEMENT) is entered into as of August 17, 2015 (the EFFECTIVE DATE) by and among THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (UTMDACC), a member institution of THE UNIVERSITY OF TEXAS SYSTEM (SYSTEM), ZIOPHARM ONCOLOGY, INC., a Delaware corporation (ZIOPHARM), and INTREXON CORPORATION, a Virginia corporation (INTREXON). ZIOPHARM and INTREXON are referenced herein collectively as the LICENSEE.

COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT BY AND BETWEEN ARQULE, INC. And BERYLLIUM DISCOVERY CORP. May 4, 2015 (August 5th, 2015)

This COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (this "Agreement") is entered into as of May 4, 2015 (the "Effective Date") by and between ArQule, Inc., a Delaware corporation with offices at One Wall Street, Burlington, MA 01803 ("ArQule"), and Beryllium Discovery Corp., a Washington corporation with offices at Preston Court, Bedford, MA 01730 ("Beryllium"). Each of Beryllium and ArQule is sometimes referred to individually herein as a "Party" and collectively as the "Parties".

Ritter Pharmaceuticals Inc – Research and Development Agreement & License (March 23rd, 2015)

This is a RESEARCH AND DEVELOPMENT AGREEMENT and LICENSE dated as of November 30, 2010 (as modified, amended or restated from time-to-time, the "Agreement") by and among: KOLU POHAKU TECHNOLOGIES, LLC, a Delaware limited liability company, with its principal place of business and mailing address at 73-4460 Queen Kaahumanu Highway, #121, Kailua-Kona, Hawaii, 96740 (together with its successors and assigns, "Kolu Pohaku"); KOLU POHAKU MANAGEMENT, LLC, a Delaware limited liability company, with its principal place of business and mailing address at 236 Third Street, Baton Rouge, Louisiana 70801 (together with its successors and assigns, "KPM"); and RITTER PHARMACEUTICALS, INC., a Delaware corporation, with its principal place of business and mailing address at 1880 Century Park East, No. 1100, Los Angeles, California 90067 (together with its successors and assigns, "Researcher"). Kolu Pohaku, KPM and Researcher are referred to collectively as the "Parties" and individually as a "Party" to

Ritter Pharmaceuticals Inc – Ritter Pharmaceuticals, Inc. Amendment No. 3 to Research and Development Agreement & License (March 23rd, 2015)

This Amendment No. 3 (the "Amendment") to the Research and Development Agreement & License, dated as of November 17, 2010, and amended on Tidy 6, 2011, and September 30, 2011 (as amended to date, the "Original Agreement"), is made and entered into as of February 6, 2012, pursuant to Section 13.4 of the Original Agreement, by and among KOLU POHAKU TECHNOLOGIES, LLC, a Delaware limited liability company (together with its successors and assigns, "Kolu Pohaku"); KOLU POHAKU MANAGEMENT, LLC, a Delaware limited liability company (together * with its successors and assigns, "KPM"); and RITTER PHARMACEUTICALS, INC., a Delaware corporation (together with its successors and assigns, the "Company"). Capitalized terms used in this Amendment that are not otherwise defined herein shall have the respective meanings assigned to them in the Original Agreement.

Ritter Pharmaceuticals Inc – Ritter Pharmaceuticals, Inc. Amendment No. 1 to Research and Development Agreement & License (March 23rd, 2015)

This Amendment No. 1 (the "Amendment") to the Research and Development Agreement & License, dated as of November 17, 2010 (the "Original Agreement"), is made and entered into as of July 6, 2011, pursuant to Section 13.4 of the Original Agreement, by and among KOLU POHAKU TECHNOLOGIES, LLC, a Delaware limited liability company (together with its successors and assigns, "Kolu Pohaku"); KOLU POHAKU MANAGEMENT, LLC, a Delaware limited liability company (together with its successors and assigns, "KPM"); and RITTER PHARMACEUTICALS, INC., a Delaware corporation (together with its successors and assigns, the "Company"). Capitalized terms used in this Amendment that are not otherwise defined herein shall have the respective meanings assigned to them in the Original Agreement.

Ritter Pharmaceuticals Inc – Ritter Pharmaceuticals, Inc. Amendment No. 2 to Research and Development Agreement & License (March 23rd, 2015)

This Amendment No. 2 (the "Amendment") to the Research and Development Agreement & License, dated as of November 17, 2010, and first amended on July 6, 2011 (as amended to date, the "Original Agreement"), is made and entered into as of September 30, 2011, pursuant to Section 13.4 of the Original Agreement, by and among KOLU POHAKU TECHNOLOGIES, LLC, a Delaware limited liability company (together with its successors and assigns, "Kolu Pohaku"); KOLU POHAKU MANAGEMENT, LLC, a Delaware limited liability company (together with its successors and assigns, "KPM"); and RITTER PHARMACEUTICALS, INC., a Delaware corporation (together with its successors and assigns, the "Company"). Capitalized terms used in this Amendment that are not otherwise defined herein shall have the respective meanings assigned to them in the Original Agreement.

Ritter Pharmaceuticals Inc – Ritter Pharmaceuticals, Inc. Amendment No. 4 to Research and Development Agreement & License (March 23rd, 2015)

This Amendment No. 4 (the "Amendment") to the Research and Development Agreement & License, dated as of November 17, 2010, and amended on July 6, 2011, September 30, 2011 and February 6, 2012 (as amended to date, the "Original Agreement"), is made and entered into as of November 4, 2013, pursuant to Section 13.4 of the Original Agreement, by and among KOLU POHAKU TECHNOLOGIES, LLC, a Delaware limited liability company (together with its successors and assigns, "Kolu Pohaku"); KOLU POHAKU MANAGEMENT, LLC, a Delaware limited liability company (together with its successors and assigns, "KPM"); and RITTER PHARMACEUTICALS, INC., a Delaware corporation (together with its successors and assigns., the "Company"). Capitalized terms used in this Amendment that are not otherwise defined herein shall have the respective meanings assigned to them in the Original. Agreement.

Omeros Corp. – Research and Development Agreement Eighth Amendment (March 16th, 2015)

This is an amendment effective 21 March 2012 (this "Amendment") of the Exclusive License and Sponsored Research Agreement dated 10 June 2004 as last amended

TRACON Pharmaceuticals – ***Text Omitted and Filed Separately With the Securities and Exchange Commission. Confidential Treatment Requested Under (December 29th, 2014)
TRACON Pharmaceuticals – Public Health Service Cooperative Research and Development Agreement for Nci Division of Cancer Treatment and Diagnosis (Dctd) Extramural Phs Clinical Research (December 29th, 2014)

This Agreement is based on the model Cooperative Research and Development Agreement (CRADA) adopted on December 8, 2010 by the U.S. Public Health Service (PHS) Technology Transfer Policy Board for use by components of the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), which are agencies of the PHS within the Department of Health and Human Services (HHS).

JOINT RESEARCH AND DEVELOPMENT AGREEMENT Between THE JOHNS HOPKINS UNIVERSITY APPLIED PHYSICS LABORATORY AND SECOND SIGHT MEDICAL PRODUCTS, INC. (October 2nd, 2014)

This Joint Research and Development Agreement ("Agreement") is made and entered into by and between The Johns Hopkins University Applied Physics Laboratory LLC ("JHU/APL"), and Second Sight Medical Products, Inc. ("Company") hereinafter collectively referred to as the Parties.

Helius Medical Technologies, Inc. – COVER SHEET Master Cooperative Research and Development Agreement (CRADA) (July 14th, 2014)
Helius Medical Technologies, Inc. – NOTICE OF MODIFICATION No. 1 of COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT Between US Army Medical Material Agency (USAMMA) a Subordinate Activity of the US Army Medical Research and Material Command (USAMRMC), in Collaboration With the Combat Casualty Care Research Program (CCCRP) and US Army Medical Material Development Activity (USAMMDA) (USAMMA and USAMMDA Collectively as Laborartory) and NeuroHabilitation Corporation (Cooperator) Yuri P. Danilov, Mitchell E. Tyler, Kurt A. Kaczmarek (Background Patent Owners) Advanced NeuroRehabilitation, LLC (Executive License of Background Patent) (July 14th, 2014)

The United States Army Medical Material Agency, 693 Neiman St, Fort Detrick, Maryland 21702-5012, U.S.A.; United States Army Medical Material Development Activity, 1430 Veterans Drive, Fort Detrick, Maryland 21702-5012, U.S.A. and NeuroHabilitation Corporation 208 Palmer Alley, Newtown, PA 18940, entered into a Cooperative Research and Development Agreement ("Agreement") (U.S. Army Medical Research and Material Command Control Number W81XWH-13-0145) on 1 February 2013, for research and development on "Collaboration to advance the Portable NeuromodulationStimulator (PoNSTM) device through FDA approval for assisted physical therapy in the treatment of soldiers and others with balance and gait disorder."

BioRestorative Therapies, Inc. – Research and Development Agreement (June 27th, 2014)

THIS RESEARCH AND DEVELOPMENT AGREEMENT (this "Agreement"), dated as of March 19, 2014 (the "Effective Date"), is made and entered into by and between BioRestorative Therapies, Inc., a Nevada corporation ("BRT"), and Rohto Pharmaceutical Co., Ltd., a Japanese corporation ("Rohto") (collectively the "Parties" or individually a "Party").

GreenPlex Services, Inc. – Product Research and Development Agreement (May 27th, 2014)

THIS AGREEMENT, effective this 21st day of May, 2014, by and between GreenPlex Services, Inc., (hereinafter referred to as GreenPlex), a public traded company domiciled in the state of Nevada having a principal place of business at 2525 E. 29th Ave., Spokane, WA 99223 and Botanical Extractor Research Group LLC, (hereinafter referred to as BERG), a private Limited Liability Company domiciled in the state of Washington and having a principle place of business at West 11514 Charles Road, Nine Mile Falls, WA 99026.

Globeimmune Inc – Contract (May 21st, 2014)

[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Globeimmune Inc – Public Health Service Cooperative Research and Development Agreement for Intramural-Phs Clinical Research (May 21st, 2014)

This Agreement is based on the model Cooperative Research and Development Agreement (CRADA) adopted by the U.S. Public Health Service (PHS) Technology Transfer Policy Board for use by components of the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), which are agencies of the PHS within the Department of Health and Human Services (HHS).

Kite Pharma, Inc. – Public Health Service Cooperative Research and Development Agreement for Intramural-Phs Clinical Research (May 19th, 2014)

This Agreement is based on the model Cooperative Research and Development Agreement (CRADA) adopted by the U.S. Public Health Service (PHS) Technology Transfer Policy Board for use by components of the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), which are agencies of the PHS within the Department of Health and Human Services (HHS).

BioRestorative Therapies, Inc. – Research and Development Agreement (May 14th, 2014)

THIS RESEARCH AND DEVELOPMENT AGREEMENT (this "Agreement"), dated as of March __, 2014 (the "Effective Date"), is made and entered into by and between BioRestorative Therapies, Inc., a Nevada corporation ("BRT"), and Rohto Pharmaceutical Co., Ltd., a Japanese corporation ("Rohto") (collectively the "Parties" or individually a "Party").

Collaborative Research and Development Agreement (May 9th, 2014)

THIS COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (this "Agreement") is made the 23rd. day of May, 2011 ("EFFECTIVE DATE") by and between the LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, a Swiss not-for-profit corporation, with its registered office at Stadelhoferstrasse 22, 8001, Zurich, Switzerland, and having an office at 666 Third Avenue, New York, NY 10017, United States of America ("LICR") and 4-ANTIBODY AG ("4AB"), incorporated in Switzerland at Schwarzwaldallee 215, CH-4002 Basel, Switzerland.

Lumena Pharmaceuticals, Inc. – Public Health Service Cooperative Research and Development Agreement for Extramural-Phs Clinical Research (April 2nd, 2014)

This Agreement (CRADA) is based on the model Cooperative Research and Development Agreement (Model CRADA) adopted by the U.S. Public Health Service (PHS) Technology Transfer Policy Board for use by components of the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), which are agencies of the PHS within the Department of Health and Human Services (HHS).

Globeimmune Inc – Public Health Service Cooperative Research and Development Agreement for Intramural-Phs Clinical Research (March 17th, 2014)

This Agreement is based on the model Cooperative Research and Development Agreement (CRADA) adopted by the U.S. Public Health Service (PHS) Technology Transfer Policy Board for use by components of the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), which are agencies of the PHS within the Department of Health and Human Services (HHS).

Globeimmune Inc – Contract (March 17th, 2014)

[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Globeimmune Inc – Contract (March 17th, 2014)

[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

*** OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. SECTION 240.24b-2 AMENDMENT NO. 4 TO RESEARCH AND DEVELOPMENT AGREEMENT (January 2nd, 2014)

This Amendment No. 4 to Research and Development Agreement, dated November 5, 2013 (this "Amendment"), is entered into by and between INTERCEPT PHARMACEUTICALS, INC., a corporation organized and existing under the laws of Delaware, with its registered office at 18 Desbrosses Street, New York, NY 10013, USA ("INTERCEPT") on the one hand and TES Pharma Srl, a corporation organized and existing under the laws of Italy, with its registered office at Via Settevalli 556, 06129, Perugia, Italy ("TES") on the other hand.

Trovagene Inc – Research and Development Agreement (May 14th, 2013)

This Research Agreement (Agreement) is between PerkinElmer Health Sciences, Inc., a Delaware corporation with a principal place of business at 940 Winter Street, Waltham, MA 02451 (PerkinElmer), and Trovagene, Inc., a Delaware corporation with a principal place of business at 11055 Flintkote Avenue, San Diego, CA 92121 (TROV), and is effective as of the date of last signature below (the Effective Date). PerkinElmer and TROV may be referred to each individually as a Party or collectively as Parties.

Biostar Pharmaceuticals – Product Research and Development Agreement (April 15th, 2013)

Party A and Party B reached the following R&D agreement regarding National Type I new medicine Danshensu Borneol Ester through friendly negotiation:

Research and Development Agreement (February 22nd, 2013)

This Amendment No. 2 to Research and Development Agreement, dated February 15, 2013, is entered into by and between INTERCEPT PHARMACEUTICALS, INC., a corporation organized and existing under the laws of Delaware, with its registered office at 18 Desbrosses Street, New York, NY 10013, USA ("INTERCEPT") on the one hand and TES Pharma Srl, a corporation organized and existing under the laws of Italy, with its registered office at Via Settevalli 556, 06129, Perugia, Italy ("TES") on the other hand.

Biologix Hair Inc. – Research and Development Agreement (January 14th, 2013)

THIS RESEARCH AND DEVELOPMENT AGREEMENT (the "Agreement") is executed as of this [ ] day of [ ], 2012, by and between Beijing BIT&GY Pharmaceutical R&D Co. Ltd., a corporation formed under the laws of the People's Republic of China ("BIT&GY"), having its principal place of business at [Building 683, 5 South Zhongguancun Street, Beijing 100081 . PR China], and Biologix Hair Science Ltd., a corporation formed under the laws of Barbados ("BHL"), having its principal place of business at The Business Center, Upton St. Michael, BB11103, Barbados. BIT&GY and BHL arc individually referred to herein as a "Party" and collectively referred to herein as the "Parties".

Cooperative Research and Development Agreement for Extramural-Phs Clinical Research (September 4th, 2012)

This Agreement is based on the model Cooperative Research and Development Agreement ("CRADA") adopted by the U.S. Public Health Service ("PHS") Technology Transfer Policy Board for use by components of the National Institutes of Health ("NIH"), the Centers for Disease Control and Prevention ("CDC"), and the Food and Drug Administration ("FDA"), which are agencies of the PHS within the Department of Health and Human Services ("HHS").

AMENDMENT Ndeg1 TO RESEARCH AND DEVELOPMENT AGREEMENT (September 4th, 2012)

by and between INTERCEPT PHARMACEUTICALS, INC., a corporation organized and existing under the laws of Delaware, with registered office at 18 Desbrosses Street, New-York 10013 NY, USA ("INTERCEPT") on the one hand and TES Pharma Srl, a corporation organized and existing under the laws of Italy, with registered office at Via Settevalli 556, 06129, Perugia, Italy ("TES") on the other hand.:

Globeimmune Inc – Public Health Service Cooperative Research and Development Agreement for Intramural-Phs Clinical Research (July 2nd, 2012)

This Agreement is based on the model Cooperative Research and Development Agreement (CRADA) adopted by the U.S. Public Health Service (PHS) Technology Transfer Policy Board for use by components of the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), which are agencies of the PHS within the Department of Health and Human Services (HHS).

Globeimmune Inc – Contract (July 2nd, 2012)

[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.